New HIV Prevention Shot Could Change Everything at $40

A groundbreaking HIV prevention medicine that only requires two shots a year is nearly 100% effective, but the pharmaceutical company controlling it won't make it affordable for most of the world.

Lenacapavir is an injectable pre-exposure prophylaxis (PrEP) that could revolutionize HIV prevention, especially for communities facing stigma and barriers to healthcare like LGBTQ+ individuals, sex workers, and people in conflict zones. The catch? Gilead Sciences charges $28,000 per year in the US, even though experts say it could be produced for less than $40.

At the International AIDS Conference in Rio de Janeiro this weekend, Doctors Without Borders (MSF) is urging Gilead to drop its price to $40 per person annually in low and middle-income countries. "We've seen firsthand what happens when medical tools like antiretroviral treatments are priced out of reach," said Renata Reis, MSF Brazil's executive director. "People die needlessly, and communities suffer."

The situation is particularly frustrating for Brazil. Brazilian communities participated in the clinical trials that helped get lenacapavir approved worldwide, yet the medicine remains largely inaccessible there. Several other Latin American countries that hosted trials, including Argentina, Mexico, and Peru, face the same problem.

Generic versions could become available next year, but Gilead is restricting which manufacturers can make them and where they can be sold. Many countries that need lenacapavir most are excluded from those deals entirely.

Why This Inspires

This story represents a pivotal moment where advocacy groups refuse to let history repeat itself. MSF has treated people with HIV/AIDS for decades and knows affordable access saves lives. They're not just asking nicely anymore.

Governments have legal tools under international trade agreements to override pharmaceutical monopolies when public health demands it. Brazil has used these measures before and could do so again. MSF recently launched a campaign encouraging people worldwide to voice support for increased access, and they're hosting a session at the conference to strategize next steps.

The medical breakthrough is real and the solution is clear: make it affordable, make it available, and watch it transform communities battling HIV across the globe.